子宫内膜癌分子分型方法综述
本文综述了分子技术用于子宫内膜癌分类的价值,讨论了组织学分类与基因型-表型相关性,强调将病理分类与TCGA替代分子分类结合用于高级别子宫内膜癌,以改善预后评估。
要点
- 分子分类应整合肿瘤形态学特征。
- 建议将病理分类与TCGA替代分子分类结合用于高级别子宫内膜癌,作为改善预后评估的选项。
- 综述讨论了分子病理在改进组织学分类缺陷及免疫治疗定制中的价值。
核心结论
- 作者建议将病理分类与TCGA替代分子分类结合用于高级别子宫内膜癌,作为改善预后评估的选项。
研究设计与样本
- 综述文章,讨论分子技术对子宫内膜癌分类的实用性,检索范围原文未报告。
主要发现
- 分子分类方案应整合肿瘤形态学特征。
- 综述讨论了基因型与表型相关性及组织学分类的近期重要进展。
- 综述讨论了组织学分类的可能缺陷及分子病理改进这些缺陷的价值,包括高级别肿瘤病理判读的观察者间变异。
- 综述讨论了将TCGA分子方法应用于临床实践的重要性、肿瘤内异质性对分类的影响,以及TCGA分类在定制免疫治疗中的实用性。
关键数值与推荐
- 原文未报告具体标准与数值。
临床怎么用
- 作者建议将病理分类与TCGA替代分子分类结合用于高级别子宫内膜癌,作为改善预后评估的选项。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Endometrial carcinoma is the most common cancer of the female genital tract. This review article discusses the usefulness of molecular techniques to classify endometrial carcinoma. Any proposal for molecular classification of neoplasms should integrate morphological features of the tumors. For that reason, we start with the current histological classification of endometrial carcinoma, by discussing the correlation between genotype and phenotype, and the most significant recent improvements. Then, we comment on some of the possible flaws of this classification, by discussing also the value of molecular pathology in improving them, including interobserver variation in pathologic interpretation of high grade tumors. Third, we discuss the importance of applying TCGA molecular approach to clinical practice. We also comment on the impact of intratumor heterogeneity in classification, and finally, we will discuss briefly, the usefulness of TCGA classification in tailoring immunotherapy in endometrial cancer patients. We suggest combining pathologic classification and the surrogate TCGA molecular classification for high-grade endometrial carcinomas, as an option to improve assessment of prognosis.
引用
- Piulats JM, Guerra E, Gil-Martín M, et al. Molecular approaches for classifying endometrial carcinoma. Gynecol Oncol. 2016. PMID: 28040204. doi:10.1016/j.ygyno.2016.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。